http://www.google.com/patents/US6469012
This selective enzyme inhibition leads to elevated cGMP levels which, in turn, provides the basis for the utilities already disclosed for the said compounds in EP-A-0463756 and EP-A-0526004, namely in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, ...
Unexpectedly, it has now been found that these disclosed compounds are useful in the treatment of erectile dysfunction.
